Related Experiment Videos
Hematologic effects of linezolid: summary of clinical experience
Stanton L Gerson1, Sheldon L Kaplan, Jon B Bruss
1Division of Hematology/Oncology and Ireland Cancer Center, Case Western Reserve University, University Hospitals of Cleveland, 10900 Euclid Avenue, Cleveland, OH 44106-4937, USA. slg5@cwru.edu
Antimicrobial Agents and Chemotherapy
|July 18, 2002
Abstract:
Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.